Merck & Company Inc's Fiscal Year is From January To December - All Figures are in USD.
The item "Diluted-EPS" stands at 7.56 United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025, the highest value at least since 03/31/2012, the period currently displayed.
Merck & Company Inc's third quarter result of 2.32 USD for the item "Diluted EPS" represents an increase of 31.46 percent compared to it's second quarter result.
Also, Merck & Company Inc's third quarter result of 2.32 USD for the item "Diluted EPS" represents an increase of 86.40 percent compared to it's third quarter result of last year.
Looking again at the trailing twelve months series (TTM), Merck & Company Inc's third quarter result of 7.56 USD for the item "Diluted EPS" represents an increase of 16.56 percent compared to it's second quarter result.
Regarding the One-Year-Change of the series, the current value constitutes an increase of 57.87 percent compared to the value the year prior.
The 1 year change in percent is 57.87.
The 3 year change in percent is 25.71.
The 5 year change in percent is 66.92.
The 10 year change in percent is 101.11.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Diluted EPS | 905,699,262,464.00 |
![]() | Johnson & Johnson - Diluted EPS | 486,508,953,600.00 |
![]() | AbbVie Inc - Diluted EPS | 399,570,305,024.00 |
![]() | Roche Holding AG - Diluted EPS | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Diluted EPS | 280,205,508,085.11 |